Find Paid Clinical Trials in Baltimore, Maryland

Paid Clinical Trials and Focus Groups by Location

All Locations ... United States » ... Maryland » ... Baltimore

Imaging of Traumatic Brain Injury

Conditions: Traumatic Brain Injury; Metabolite Changes; Cerebral Perfusion; Hemorrhagic Burden
Intervention:
Sponsor: University of Maryland
Recruiting - verified September 2010
Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Linagliptin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Not yet recruiting - verified September 2010
Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms

Conditions: Ductal Carcinoma In Situ; Estrogen Receptor-positive Breast Cancer; Progesterone Receptor-positive Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: letrozole; Drug: zoledronic acid; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Other: mass spectrometry; Procedure: bone scan; Procedure: quality-of-life assessment; Other: questionnaire administration; Other: pharmacogenomic studies; Other: high performance liquid chromatography
Sponsor: Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting - verified September 2010
Study to Evaluate the Effects of TRV120027 in Patients With Heart Failure

Condition: Heart Failure
Interventions: Drug: TRV120027; Drug: Placebo
Sponsor: Trevena Inc.
Not yet recruiting - verified August 2010
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

Conditions: Lymphoblastic Leukemia, Acute; Lymphoblastic Leukemia, Acute, Childhood; Leukemia, Lymphoblastic, Acute, T Cell; Leukemia, Lymphoblastic, Acute
Interventions: Drug: EZN-3042; Drug: Cytarabine; Drug: Doxorubicin; Drug: Prednisone; Drug: Vincristine; Drug: Pegaspargase; Drug: Methotrexate
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Enzon Pharmaceuticals, Inc.
Recruiting - verified August 2010
Salsalate for Insulin Resistance in Schizophrenia

Conditions: Schizophrenia; Insulin Resistance
Intervention: Drug: salsalate
Sponsors: University of Maryland; Department of Veterans Affairs
Not yet recruiting - verified August 2010
Dietary Interventions in Asthma Treatment: Sprouts Study

Conditions: Asthma; Allergy
Intervention: Other: Broccoli Sprouts
Sponsors: Johns Hopkins University; National Institutes of Health (NIH); Massachusetts General Hospital
Not yet recruiting - verified August 2010
A Research Trial of Aralast in New Onset Diabetes (RETAIN) - Part I

Condition: Diabetes Mellitus, Type 1
Intervention: Drug: Alpha 1-Antitrypsin (AAT, Aralast NP)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network; Juvenile Diabetes Research Foundation
Not yet recruiting - verified August 2010
A Research Trial of Aralast in New Onset Diabetes (RETAIN) - Part II

Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Alpha 1-Antitrypsin (AAT, Aralast NP); Drug: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network; Juvenile Diabetes Research Foundation
Not yet recruiting - verified August 2010
IV Iron for the Anemia of Traumatic Critical Illness

Conditions: Trauma; ICU Anemia
Interventions: Drug: Iron sucrose; Drug: Placebo
Sponsors: Denver Health and Hospital Authority; National Trauma Institute
Not yet recruiting - verified August 2010
Medications Development for Drug Abuse Disorders

Conditions: Opioid Related Disorders; Opioid Dependence; Opioid Addiction
Interventions: Drug: Buprenorphine/naloxone; Drug: Clonidine; Drug: Tramadol ER
Sponsors: Johns Hopkins University; National Institute on Drug Abuse (NIDA)
Not yet recruiting - verified August 2010
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A Long Term Evaluation

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide; Drug: placebo
Sponsor: Novo Nordisk
Recruiting - verified September 2010
A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection

Condition: Rhinovirus
Interventions: Drug: BTA798; Drug: Placebo
Sponsor: Biota Scientific Management Pty Ltd
Recruiting - verified August 2010
Influenza Antiviral DAS181-F03

Condition: Influenza
Interventions: Drug: DAS181; Drug: Placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified July 2010
Gene Expression in Inflammatory Bowel Disease

Condition: Inflammatory Bowel Disease
Intervention:
Sponsor: Johns Hopkins University
Recruiting - verified August 2010
Evaluation of Tiotropium 2.5 and 5 Mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 Mcg Twice Daily) in Patient With Moderate Persistent Asthma I

Condition: Asthma
Interventions: Drug: 2.5 mcg tiotropium Respimat®; Drug: 5 mcg tiotropium Respimat®; Drug: 50 mcg salmeterol HFA MDI; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Not yet recruiting - verified August 2010
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer

Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: FOLFIRI regimen; Drug: FOLFOX regimen; Drug: capecitabine; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: mitomycin C; Drug: oxaliplatin; Procedure: therapeutic conventional surgery
Sponsors: Walter Reed Army Medical Center; National Cancer Institute (NCI)
Recruiting - verified September 2010
Johns Hopkins Crohn's Disease and Ulcerative Colitis Study

Condition: Inflammatory Bowel Disease
Intervention:
Sponsor: Johns Hopkins University
Recruiting - verified August 2010
A Coping Effectiveness Training Intervention for Caregivers of Children With Autism Spectrum: A Feasibility Study

Condition: Autism Spectrum Disorders
Intervention: Behavioral: Coping Effectiveness Training
Sponsor: National Human Genome Research Institute (NHGRI)
Recruiting - verified June 2010
Multi-center Evaluation of the VERSANT® CT/GC DNA 1.0 Assay (kPCR)in Detecting C. Trachomatis and N. Gonorrhoeae

Conditions: Chlamydia; Gonorrhea
Intervention:
Sponsor: Siemens Healthcare Diagnostics Inc
Recruiting - verified August 2010
Intervention for Toddlers at Risk for Autism Spectrum Disorders (ASD)

Condition: Autism Spectrum Disorder
Interventions: Behavioral: Playgroup; Behavioral: Parent Training/Enrichment Sessions; Behavioral: Individual Parent Therapeutic Sessions
Sponsors: Johns Hopkins University; Autism Speaks
Recruiting - verified July 2010
Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

Condition: Hepatitis C Virus
Interventions: Drug: BMS-790052; Drug: BMS-790052; Drug: Placebo; Drug: peginterferon alfa-2a; Drug: ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified July 2010
Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant

Condition: Septicemia
Interventions: Biological: CpG 7909; Biological: J5-OMP Vaccine; Drug: Placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified July 2010
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged >= 50 Years

Condition: Herpes Zoster
Interventions: Biological: Herpes Zoster Vaccine GSK1437173A; Biological: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified August 2010
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

Condition: Hypertension, Pulmonary
Interventions: Drug: ambrisentan; Drug: tadalafil
Sponsors: GlaxoSmithKline; Gilead Sciences
Not yet recruiting - verified August 2010
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged >= 70 Years

Conditions: Herpes Zoster; Herpes Zoster Vaccine
Interventions: Biological: Herpes Zoster Vaccine GSK1437173A; Biological: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified August 2010
OIT and Xolair® (Omalizumab) in Cow's Milk Allergy

Condition: Milk Allergy
Interventions: Biological: Xolair® (omalizumab) placebo/milk OIT; Biological: Xolair® (omalizumab)/milk OIT
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified July 2010
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia

Conditions: Minimal Residual Disease; Leukemia, Lymphoblastic, Acute; Leukemia, Myelogenous, Acute
Interventions: Drug: Clofarabine; Drug: Cytarabine; Drug: Methotrexate; Drug: Cytarabine
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Genzyme
Recruiting - verified August 2010
Dose Escalation of IPI-493 in Hematologic Malignancies

Condition: Hematologic Malignancies
Intervention: Drug: IPI-493
Sponsor: Infinity Pharmaceuticals
Recruiting - verified August 2010
Neurobiology and Pharmacokinets of Acute MDMA Administration

Condition: Substance-Related Disorders
Interventions: Drug: MDMA; Drug: (+/-)3,4-methylenedioxymethamphetamine Hydrochloride, MDMA HCI Capsules
Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting - verified September 2009
Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures

Condition: Partial Onset Seizures
Interventions: Drug: BGG492; Drug: Placebo
Sponsor: Novartis
Recruiting - verified August 2010
Phase II Tularemia Vaccine Comparison

Condition: F. Tularensis (Tularemia)
Interventions: Biological: Dynport Vaccine Company LVS (DVC-LVS); Drug: Placebo; Biological: United States Army Medical Research Institute of Infectious Diseases LVS (USAMRIID-LVS)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified July 2010
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsor: Sanofi-Aventis
Recruiting - verified September 2010
Phase I Study of ETEC Vaccine

Condition: Escherichia Coli Infections
Intervention: Biological: Double Mutant Heat- Labile Toxin (dmLT)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2010
Multi-Center African-American Inflammatory Bowel Disease Study (MAAIS): The Search for New Genes

Condition: Inflammatory Bowel Disease
Intervention:
Sponsors: Johns Hopkins University; National Institutes of Health (NIH); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Crohn's and Colitis Foundation; The Johns Hopkins Meyerhoff Inflammatory Bowel Disease Center; Howard University; Washington Hospital Center; University of North Carolina; University of Florida; Henry Ford Hospital
Recruiting - verified August 2010
Safety and Tolerability Study of N6022 in Healthy Subjects

Condition: Healthy Subjects
Interventions: Drug: N6022; Drug: Placebo
Sponsor: N30 Pharmaceuticals LLC
Recruiting - verified August 2010
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free

Condition: Sarcoma
Interventions: Biological: Trivalent ganglioside vaccine; Biological: OPT-821
Sponsor: MabVax Therapeutics, Inc.
Recruiting - verified June 2010
Face Transplantation

Condition: Transplantation: Facial Transplantation
Intervention: Procedure: Face Transplant
Sponsors: University of Maryland; Department of Defense
Recruiting - verified September 2010
Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression

Condition: Parkinson Disease
Intervention:
Sponsors: Michael J. Fox Foundation for Parkinson's Research; Institute for Neurodegenerative Disorders
Recruiting - verified August 2010
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept; Drug: Methotrexate; Drug: Abatacept Placebo; Drug: Methotrexate Placebo
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified June 2010
Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)

Condition: Non-small Cell Lung Cancer
Interventions: Drug: imetelstat; Drug: Bevacizumab
Sponsor: Geron Corporation
Recruiting - verified August 2010
A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals

Conditions: Opioid Abuse; Opioid Dependence
Interventions: Drug: buprenorphine; Drug: morphine
Sponsors: Johns Hopkins University; National Institute on Drug Abuse (NIDA)
Recruiting - verified August 2010
Assessing Top Down and Bottom Up Attention Mechanisms in Smokers Using Nicotine Nasal Spray

Conditions: Drug Addiction; Nicotine Dependence
Intervention: Drug: Nicotrol
Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting - verified December 2009
Reduced-intensity, Partially Mismatched, BMT With Flu-bu and Post Hi-Cy

Conditions: Lymphoma; Leukemia; Myelodysplastic Syndrome
Intervention: Drug: Fludarabine, Busulfan, Cyclophosphamide, Tacrolimus,
Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified September 2010
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

Condition: Acromegaly
Interventions: Drug: Pasireotide (SOM230); Drug: octreotide LAR 30mg or lanreotide ATG 120mg
Sponsor: Novartis Pharmaceuticals
Not yet recruiting - verified September 2010
Study of BMS-790052 Add-On to Standard of Care in Treatment Naive Subjects

Condition: Hepatitis C Virus
Interventions: Drug: BMS-790052; Drug: BMS-790052; Drug: Placebo; Drug: peg-interferon alfa-2a; Drug: ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified May 2010
A Study of Family-based Cognitive-behavioral Therapy for Chronic Pediatric Headache and Anxiety

Conditions: Pediatric; Headache; Anxiety
Intervention: Behavioral: CBT or relaxation training
Sponsors: Johns Hopkins University; Migraine Research Foundation
Recruiting - verified May 2010
Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Condition: Alzheimer's Disease
Intervention: Drug: Solanezumab
Sponsor: Eli Lilly and Company
Not yet recruiting - verified August 2010
Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2

Condition: Type 1 Diabetes Mellitus
Interventions: Biological: Otelixizumab; Biological: Placebo
Sponsors: Tolerx Inc.; Juvenile Diabetes Research Foundation; GlaxoSmithKline
Recruiting - verified May 2010
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium 2.5 mcg; Drug: tiotropium 5 mcg; Drug: Tiotropium 18 mcg; Drug: placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Tracking Renal Tumors After Cryoablation Evaluation

Condition: Kidney Neoplasms
Intervention: Procedure: Cryoablation
Sponsor: Galil Medical
Recruiting - verified September 2010
Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: azacitidine; Drug: entinostat; Genetic: DNA methylation analysis; Genetic: gene expression analysis; Genetic: polymerase chain reaction; Genetic: reverse transcriptase-polymerase chain reaction; Genetic: western blotting; Other: laboratory biomarker analysis
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified August 2010
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

Condition: Dyslipidemia
Interventions: Drug: LY2484595; Drug: Atorvastatin; Drug: Simvastatin; Drug: Rosuvastatin; Drug: Placebo for LY2484595; Drug: Placebo for Statins
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Web-delivery of Evidence-based, Psychosocial Treatment for Substance Use Disorders

Condition: Substance Abuse
Interventions: Behavioral: Therapeutic Education System; Behavioral: Treatment-as-Usual (TAU)
Sponsor: National Institute on Drug Abuse (NIDA)
Not yet recruiting - verified August 2010
A Twenty-eight Week Safety, Extension Study of Flibanserin to Treat Premenopausal and Postmenopausal Women With Hypoactive Sexual Desire Disorder

Condition: Sexual Dysfunctions, Psychological
Intervention: Drug: flibanserin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Conditions: Acute Coronary Syndrome; Gout
Interventions: Drug: Febuxostat; Drug: Allopurinol
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified September 2010
A Phase 3 Study of Brentuximab Vedotin (SGN-35) for Prevention of Hodgkin Lymphoma Progression (The AETHERA Trial)

Condition: Disease, Hodgkin
Interventions: Drug: brentuximab vedotin; Drug: placebo
Sponsors: Seattle Genetics, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified August 2010
ACT-293987 in Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: ACT-293987; Drug: Placebo
Sponsor: Actelion
Recruiting - verified August 2010
A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer

Conditions: Stage I Breast Cancer; Stage II Breast Cancer; Stage III Breast Cancer; Invasive Breast Cancer
Intervention: Drug: Vorinostat and Tamoxifen
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Merck
Not yet recruiting - verified September 2010
Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis

Condition: Cystic Fibrosis
Intervention: Drug: sodium chloride (7%)
Sponsors: University of North Carolina, Chapel Hill; Novartis Pharmaceuticals; Johns Hopkins University
Recruiting - verified September 2010
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia

Condition: Leukemia
Intervention: Drug: Bendamustine
Sponsor: Cephalon
Recruiting - verified August 2010
Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome

Condition: Acute Coronary Syndrome
Intervention: Drug: ADP receptor inhibitors
Sponsors: Eli Lilly and Company; Daiichi Sankyo Inc.
Recruiting - verified August 2010
Investigation in Pregnancy Associate Cardiomyopathy

Conditions: Cardiomyopathy; Pregnancy
Intervention:
Sponsors: University of Pittsburgh; National Institutes of Health (NIH)
Recruiting - verified August 2010
A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)

Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ABT-263; Drug: rituximab
Sponsors: Genentech; Abbott
Recruiting - verified August 2010
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Condition: Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Interventions: Biological: Rituximab; Other: Placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2010
Relapse-Prevention Study With F2695 SR in Patients With Major Depressive Disorder

Conditions: Depression; Major Depressive Disorder
Interventions: Drug: F2695 SR; Drug: Placebo
Sponsor: Forest Laboratories
Recruiting - verified August 2010
Paclitaxel, Cisplatin, and Cetuximab Followed By Cetuximab and Intensity-Modulated Radiation Therapy in Treating Patients With HPV-Associated Stage III or Stage IV Cancer of the Oropharynx That Can Be Removed By Surgery

Conditions: Head and Neck Cancer; Precancerous Condition
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: Donepezil; Drug: Placebo
Sponsor: Pfizer
Not yet recruiting - verified August 2010
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection

Condition: Chronic Hepatitis B Virus, Pediatric
Interventions: Drug: Entecavir; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified July 2010
A Trial of Boost Vaccinations of Pancreatic Tumor Cell Vaccine

Condition: Pancreatic Cancer
Intervention: Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine.
Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified August 2010
Alzheimer's Disease Neuroimaging Initiative Grand Opportunity

Conditions: Mild Cognitive Impairment; Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); National Institute on Aging (NIA); National Institutes of Health (NIH)
Recruiting - verified August 2010
Febuxostat Versus Allopurinol or Placebo in Subjects With Hyperuricosuria and Calcium Oxalate Stones

Conditions: Hyperuricosuria; Kidney Stones
Interventions: Drug: Febuxostat; Drug: Allopurinol; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified September 2010
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen

Conditions: Lymphoma, Non-Hodgkin; Lymphoma, Follicular
Interventions: Drug: Ofatumumab and Bendamustine infusions (Arm A); Drug: Bendamustine infusion (Arm B)
Sponsor: GlaxoSmithKline
Not yet recruiting - verified August 2010
An Early Safety and Efficacy Study of Ascites Management: Standard Paracentesis or Early Intervention With Pleurx Catheters in Patients With Malignant Ascites

Condition: Malignant Ascites
Interventions: Procedure: paracentesis; Device: Pleurx catheter
Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified September 2010
Oral Fluid, Plasma and Whole Pharmacokinetics and Stability Following Smoked Cannabis

Conditions: Cannabis Use; Drug Abuse
Intervention: Drug: Cannabis Cigarette
Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting - verified December 2009
A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

Conditions: Hypertension, Pulmonary; Ventricular Dysfunction, Left
Interventions: Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Placebo
Sponsor: Bayer
Recruiting - verified August 2010
An Efficacy and Safety Study of Dapoxetine in Men With Premature Ejaculation and Concomitant Erectile Dysfunction Treated With a Phosphodiesterase-5 Inhibitor (ie, Sildenafil, Vardenafil, or Tadalafil)

Conditions: Erectile Dysfunction; Sexual Dysfunction
Interventions: Drug: Placebo; Drug: Dapoxetine
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Nebivolol in Patients With Systolic Stage 2 Hypertension

Condition: Hypertension
Interventions: Drug: Nebivolol; Drug: Placebo
Sponsor: Forest Laboratories
Recruiting - verified August 2010
Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias

Conditions: Spinocerebellar Ataxia Type 1; Spinocerebellar Ataxia Type 2; Spinocerebellar Ataxia Type 3; Spinocerebellar Ataxia Type 6
Intervention:
Sponsors: University of Florida; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified August 2010
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified August 2010
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Interferon β 1a; Drug: DAC HYP
Sponsors: Biogen Idec; Facet Biotech
Recruiting - verified August 2010
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: cixutumumab; Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: irinotecan hydrochloride; Drug: temozolomide; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo

Condition: Hepatitis C, Chronic
Intervention: Drug: Telaprevir/standard treatment
Sponsors: Tibotec Pharmaceuticals, Ireland; Vertex Pharmaceuticals Incorporated
Recruiting - verified August 2010
The Neural Basis of Cue-elicited Cigarette Craving and Its Control

Condition: Nicotine Dependence
Intervention: Behavioral: Real Time Feedback Training
Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting - verified July 2010
A Study for Patients With Type 1 Diabetes

Condition: Diabetes Mellitus, Type 1
Interventions: Drug: LY2605541; Drug: Insulin glargine
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries

Condition: Encephalitis
Interventions: Biological: IC51; Biological: IC51; Biological: IC51
Sponsor: Intercell AG
Recruiting - verified January 2010
12 Week Safety Trial of Flibanserin in Depressed Women Taking a Selective Serotonin Reuptake Inhibitor or Norepinephrine Serotonin Reuptake Inhibitor With Decreased Sexual Desire and Distress

Conditions: Sexual Dysfunctions, Psychological; Depression
Interventions: Drug: flibanserin 2; Drug: placebo; Drug: flibanserin 1
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug Dependence

Conditions: Schizophrenia; Drug Abuse/Dependency
Intervention:
Sponsors: National Institute on Drug Abuse (NIDA); University of Maryland
Recruiting - verified June 2010
Measuring Distress Tolerance With Functional MRI

Condition: Cocaine Dependence
Intervention:
Sponsors: National Institute on Drug Abuse (NIDA); University of Maryland
Recruiting - verified August 2010
Effects of Sativex(Registered Trademark) and Oral THC on Attention, Affect, Working Memory, Reversal Learning, Physiology and Brain Activation

Conditions: Cannabis; Dependence; Cannabis Abuse; Pharmacokinetics; fMRI
Interventions: Drug: Sativex(Registered Trademark); Drug: THC
Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting - verified January 2010
Spinal Cord Stimulation With Precision® SCS System Versus Reoperation for Failed Back Surgery Syndrome

Conditions: Failed Back Surgery Syndrome; Leg Pain; Back Pain; Spinal Cord Stimulation
Interventions: Device: Precision Spinal Cord Stimulation; Procedure: Back Surgery
Sponsor: Boston Scientific Corporation
Recruiting - verified August 2010
Effects of Nicotine on Brain Activity as Measured by fMRI

Conditions: Nicotine Dependence; Drug Abuse
Intervention:
Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting - verified August 2010
Cognitive Task Development and Implementation for Functional MRI Studies

Condition: Drug Abuse
Intervention:
Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting - verified August 2010
Reward Processing in Cocaine Addiction

Conditions: Drug Abuse; Cocaine Dependence
Intervention:
Sponsors: National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH)
Recruiting - verified August 2010
Effects of Nicotine on Areas of Impaired and Preserved Functioning in Schizophrenia

Conditions: Nicotine Dependence; Schizophrenia
Intervention:
Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting - verified August 2010
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension

Conditions: Type 2 Diabetes Mellitus; Cardiovascular Disease; Hypertension; Inadequate Glycaemic Control
Interventions: Drug: Dapagliflozin; Drug: Placebo
Sponsors: AstraZeneca; Bristol-Myers Squibb
Recruiting - verified August 2010
Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

Condition: Hepatitis C Virus
Interventions: Drug: BMS-650032; Drug: BMS-650032; Drug: BMS-650032; Drug: BMS-650032; Drug: Peginterferon Alfa-2a; Drug: Peginterferon Alfa-2a; Drug: Ribavirin; Drug: Ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified August 2010
Immunogenicity of Off-Schedule Dosing of HPV Vaccine

Condition: Human Papillomavirus
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2010
Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.

Condition: Multiple Sclerosis
Intervention: Drug: Betaseron (Interferon beta-1b, BAY86-5046)
Sponsor: Bayer
Recruiting - verified September 2010
A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Biological: BI-505
Sponsor: BioInvent International AB
Recruiting - verified August 2010
Intravenous BI 6727 in 2nd Line Treatment of Urothelial Cancer

Condition: Neoplasms
Intervention: Drug: BI 6727, IV infusion
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis

Condition: Perennial Allergic Rhinitis
Interventions: Drug: Azelastine hydrochloride nasal spray 0.15%; Drug: Azelastine hydrochloride nasal spray 0.10%; Drug: Placebo
Sponsor: Meda Pharmaceuticals
Recruiting - verified August 2010
Prenatal Drug Exposure: Effects on the Adolescent Brain and Behavior Development

Conditions: Drug Abuse; Prenatal Drug Exposure
Intervention:
Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting - verified August 2010
A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: taspoglutide; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma

Condition: Sarcoma
Interventions: Drug: bortezomib; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2010
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery

Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: erlotinib hydrochloride; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Condition: Chronic Hepatitis C
Interventions: Drug: BMS-790052; Drug: BMS-650032; Drug: pegylated-interferon-α; Drug: ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified June 2010
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

Condition: Sarcoma
Interventions: Biological: bevacizumab; Biological: filgrastim; Biological: pegfilgrastim; Drug: docetaxel; Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery

Conditions: Colorectal Cancer; Precancerous Condition
Interventions: Drug: rosuvastatin; Other: placebo
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified September 2010
CLL11: A Study of RO5072759 With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: RO5072759; Drug: rituximab; Drug: chlorambucil
Sponsors: Hoffmann-La Roche; Genentech; German CLL Study Group
Recruiting - verified August 2010
Managerial Database II

Condition: HIV
Intervention: Other: Observation
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH)
Recruiting - verified July 2010
Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer

Condition: Liver Cancer
Interventions: Biological: cixutumumab; Drug: sorafenib tosylate; Other: laboratory biomarker analysis
Sponsors: California Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified January 2010
Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial

Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: Southern blotting; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2010
Study of Bone Marrow and Blood Samples in Patients With Untreated Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Enrolled on Clinical Trial CALGB-9621 or CALGB-9720

Condition: Leukemia
Intervention: Other: laboratory biomarker analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2010
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

Conditions: Lymphoma; Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure; Other: informational intervention
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
A Study of Duloxetine in Major Depressive Disorder (MDD) and Associated Painful Symptoms

Condition: Major Depressive Disorder
Interventions: Drug: Duloxetine; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma

Condition: Leukemia-Lymphoma, Adult T-Cell
Intervention: Drug: Etoposide, Vincristine, Doxorubicin, Prednisone, Cyclophosphamide (EPOCH) with Bortezomib and Raltegravir
Sponsor: Washington University School of Medicine
Recruiting - verified August 2010
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group
Recruiting - verified September 2010
Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: belinostat; Drug: carboplatin
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women

Conditions: HIV Infections; H1N1 Influenza Virus
Intervention: Biological: Influenza A (H1N1) monovalent vaccine
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2009
Red Cell Storage Duration Study

Conditions: Cardiac Surgery; Erythrocyte Transfusion
Interventions: Biological: Red blood cell units stored <= 10 days; Biological: Red blood cell units stored >= 21 days
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified September 2010
6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes

Condition: Type 1 Diabetes Mellitus
Interventions: Drug: INSULIN GLARGINE (HOE901); Drug: Neutral Protamine Hagedorn (NPH) insulin
Sponsor: Sanofi-Aventis
Recruiting - verified September 2010
A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Diabetic Painful Neuropathy

Conditions: Pain; Diabetic Neuropathy, Painful
Interventions: Drug: Placebo; Drug: JNJ-42160443
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

Condition: Coronary Artery Disease
Interventions: Drug: Apadenoson; Drug: Adenosine
Sponsors: PGxHealth, LLC; PPD
Recruiting - verified August 2010
Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: paclitaxel; Drug: veliparib
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers

Conditions: Tuberculosis; HIV
Interventions: Drug: Efavirenz (EFV); Drug: TMC207
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2009
Carboplatin and Paclitaxel Combined With Cetuximab and/or Cixutumumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: cetuximab; Biological: cixutumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Evaluation of Trinity Evolution in Patients Undergoing Foot and Ankle Fusion

Conditions: Tibiotalar Arthrodesis; Subtalar Arthrodesis; Calcaneocuboid Arthrodesis; Talonavicular Arthrodesis; Double Arthrodesis (i.e. Calcaneocuboid and Talonavicular); Triple Arthrodesis (i.e. Subtalar, Calcaneocuboid, and Talonavicular)
Intervention: Biological: Trinity Evolution
Sponsor: Orthofix Inc.
Recruiting - verified August 2010
A Pilot Study for Collection of Anti-Influenza A H1N1 (Swine Flu) Plasma

Conditions: H1N1 Influenza; Swine Flu
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2009
Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

Conditions: Hepatitis C; HIV Infections
Interventions: Drug: telaprevir or matching placebo; Drug: telaprevir or matching placebo; Biological: peginterferon alfa-2a; Drug: ribavirin (fixed dose); Drug: ribavirin (weight-based dose)
Sponsors: Vertex Pharmaceuticals Incorporated; Tibotec Pharmaceutical Limited
Recruiting - verified August 2010
Radiation Therapy and Cisplatin in Treating Patients With Stage I Bladder Cancer

Condition: Bladder Cancer
Interventions: Drug: cisplatin; Radiation: 3-dimensional conformal radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer

Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

Conditions: Brain and Central Nervous System Tumors; Neurotoxicity
Interventions: Drug: temozolomide; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: ixabepilone; Drug: paclitaxel; Drug: temsirolimus
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Phase I STEBVax in Healthy Adults

Condition: Staphylococcus Enterotoxin B
Intervention: Biological: STEBVax
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified June 2010
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

Conditions: Relapsed T-Cell Acute Lymphoblastic Leukemia; Relapsed T-Cell Lymphoblastic Lymphoma
Interventions: Drug: Nelarabine; Drug: Etoposide; Drug: Cyclophosphamide; Drug: Methotrexate; Drug: Filgrastim
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; GlaxoSmithKline
Recruiting - verified August 2010
Voyager I: Patient Discharge Using the AB5000 Portable Driver System

Condition: Acute Cardiac Dysfunction
Intervention: Device: AB Portable Driver System
Sponsor: Abiomed Inc.
Recruiting - verified August 2010
Cardiovascular Disease Education and Problem-Solving Training in People With Type 2 Diabetes

Condition: Type 2 Diabetes
Interventions: Behavioral: Education + Problem-Solving Training Self-Study; Behavioral: Education + Group Problem-Solving Training; Behavioral: Education + Individual Problem-Solving Training; Behavioral: Usual Care
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 2010
Multisite Controlled Trial of Cocaine Vaccine TA-CD09

Condition: Cocaine Dependence
Interventions: Drug: TA-CD Vaccination; Other: Placebo Injection
Sponsors: National Institute on Drug Abuse (NIDA); US Department of Veterans Affairs Cooperative Studies Program; VA Maryland Health Care System; Baylor College of Medicine; Columbia University; VA New York Harbor Healthcare System; University of Pennsylvania; Johns Hopkins University; University of Cincinnati; Celtic Pharma Development Services
Recruiting - verified August 2010
A Study to Evaluate the Effectiveness and Safety of MEDI-528 in Adults

Condition: Asthma
Interventions: Biological: MEDI-528; Biological: MEDI-528; Biological: MEDI-528; Other: Placebo
Sponsor: MedImmune LLC
Recruiting - verified September 2010
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified August 2010
Study of Blood Samples From Newborns With Down Syndrome

Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: RNA analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
A Study in Relapse Prevention of Treatment-resistant Depression

Condition: Treatment Resistant Depression
Interventions: Drug: Olanzapine and Fluoxetine combination; Drug: Fluoxetine
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine or Ovarian Cancer

Conditions: Ovarian Cancer; Sarcoma
Interventions: Drug: carboplatin; Drug: ifosfamide; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis

Condition: Sarcoidosis
Interventions: Drug: Placebo; Drug: golimumab; Drug: ustekinumab
Sponsor: Centocor, Inc.
Recruiting - verified August 2010
Study of Patients With Advanced Non-Small Cell Lung Cancer

Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Carboplatin; Drug: Paclitaxel; Biological: Bevacizumab
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Treatment Use of Generex Oral-lyn™ in Patients With Diabetes

Condition: Diabetes Mellitus
Intervention: Drug: Generex Oral-lyn™
Sponsor: Generex Biotechnology Corp.
Available - verified September 2010
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: vincristine sulfate; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018

Condition: Benign Prostatic Hyperplasia (BPH)
Interventions: Drug: NX-1207; Drug: Placebo
Sponsor: Nymox Corporation
Recruiting - verified August 2010
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage III or Stage IVA Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; University of Chicago; Dana-Farber Cancer Institute; Georgetown University; Johns Hopkins University; M.D. Anderson Cancer Center; University of Alabama at Birmingham; University of California, San Francisco; University of North Carolina; Duke University; Vanderbilt-Ingram Cancer Center; The Indiana University Simon Cancer Center; Mayo Clinic; University of Pittsburgh; University of Michigan Health System
Recruiting - verified September 2010
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients

Condition: Diabetes Mellitus, Type 2
Intervention: Drug: linagliptin QD for 7 days
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder

Condition: Overactive Bladder
Interventions: Drug: Fesoterodine; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified August 2010
Evaluation of the Brainsway Deep Transcranial Magnetic Stimulation (TMS) H-Coil in the Treatment of Major Depression Disorder

Condition: Major Depressive Disorder
Interventions: Device: Brainsway H-Coil Deep TMS System; Device: Brainsway H-Coil Deep TMS System (Sham treatment)
Sponsor: Brainsway
Recruiting - verified August 2010
Efficacy of Combination Therapies for Gonorrhea Treatment

Condition: Gonococcal Infections
Interventions: Drug: Azithromycin; Drug: Gemifloxacin; Drug: Gentamicin
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2010
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Teplizumab (MGA031); Drug: Placebo
Sponsors: MacroGenics; Eli Lilly and Company
Recruiting - verified September 2010
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
The National Standard for Normal Fetal Growth

Conditions: Pregnancy; Fetal Growth
Intervention:
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2010
Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally

Condition: Variola Major (Smallpox)
Interventions: Biological: IMVAMUNE® (liquid, intradermal); Biological: IMVAMUNE® (liquid, subcutaneous); Biological: IMVAMUNE® (lyophilized)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2010
Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery

Condition: Cardiac Surgery Requiring Cardiopulmonary Bypass
Interventions: Drug: recombinant factor XIII; Drug: recombinant factor XIII; Drug: placebo
Sponsor: Novo Nordisk
Recruiting - verified August 2010
A Study of Liposomal Doxorubicin With or Without IMC-3G3 in Platinum-refractory or Resistant Advanced Ovarian Cancer

Condition: Ovarian Neoplasms
Interventions: Biological: IMC-3G3; Drug: liposomal doxorubicin
Sponsor: ImClone LLC
Recruiting - verified September 2010
Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59

Condition: Influenza
Interventions: Biological: MF-59; Drug: Placebo; Biological: A/Anhui/05
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2010
Cipro Inhaler for Cystic Fibrosis Children Ages 6-12

Condition: Pseudomonas Infection
Intervention: Drug: Ciprofloxacin (Cipro, BAYQ3939)
Sponsor: Bayer
Recruiting - verified August 2010
Eslicarbazepine Acetate Monotherapy Long Term Study

Condition: Epilepsy
Intervention: Drug: Eslicarbazepine acetate
Sponsor: Sepracor, Inc.
Recruiting - verified April 2010
Primovist / Eovist in Renally Impaired Patients

Condition: Contrast Media
Intervention: Drug: Eovist (Primovist, BAY86-4873)
Sponsor: Bayer
Recruiting - verified September 2010
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Condition: Neuroblastoma
Interventions: Genetic: loss of heterozygosity analysis; Other: cytology specimen collection procedure; Procedure: biopsy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
A Phase 1 Dose-escalation Study of a Cell Cycle Inhibitor With and Without Cytarabine in Patients With Acute Leukemias (Study P05247)

Conditions: Myelogenous Leukemia, Acute; Leukemia, Lymphocytic, Acute; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive; Myelogenous Leukemia, Chronic, Aggressive Phase
Interventions: Drug: SCH 900776; Drug: Cytarabine
Sponsor: Schering-Plough
Recruiting - verified August 2010
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Conditions: Cancer; Colon Cancer; Colorectal Cancer; Fever; Locally Advanced; Metastatic Colorectal Cancer; Neutropenia; Rectal Cancer
Interventions: Drug: Pegfilgrastim; Drug: Placebo
Sponsor: Amgen
Recruiting - verified September 2010
Efficacy and Safety Study of BIIB017

Condition: Relapsing Multiple Sclerosis
Intervention: Drug: BIIB017
Sponsor: Biogen Idec
Recruiting - verified August 2010
Effect of LY2062430 on the Progression of Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: LY2062430; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Study of Kidney Tumors in Young Patients

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes

Conditions: Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Intervention: Other: biologic sample preservation procedure
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2010
Collecting and Storing Biological Samples From Young Patients With Hodgkin's Lymphoma

Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma

Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Collecting Tumor Samples From Patients With Gynecological Tumors

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma

Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva
Sponsor: Bayer
Recruiting - verified August 2010
Imatinib in Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: QTI571; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified August 2010
Ventavis® Registry Protocol

Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Commercial Ventavis® (iloprost)
Sponsor: Actelion
Recruiting - verified August 2010
Safety Follow-Up to HP 802-247-09-015

Conditions: Venous Leg Ulcer; Venous Stasis Ulcer
Intervention:
Sponsor: Healthpoint
Recruiting - verified August 2010
Citalopram for Agitation in Alzheimer's Disease

Conditions: Alzheimer's Disease; Agitation
Interventions: Drug: citalopram; Drug: placebo
Sponsors: Johns Hopkins University; National Institute on Aging (NIA); National Institute of Mental Health (NIMH)
Recruiting - verified September 2010
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Collecting and Storing Tissue From Young Patients With Cancer

Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: DNA methylation analysis; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: reverse transcriptase-polymerase chain reaction; Other: high performance liquid chromatography; Other: laboratory biomarker analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2010
Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma

Condition: Brain and Central Nervous System Tumors
Interventions: Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: docetaxel; Drug: doxorubicin; Drug: cyclophosphamide; Drug: cyclophosphamide; Drug: pegfilgrastim
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); Genentech; US Oncology Research
Recruiting - verified August 2010
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs

Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]; Drug: Nonbiologic DMARDs of investigator's choice
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents

Condition: Crohn's Disease
Interventions: Drug: certolizumab pegol; Drug: certolizumab pegol
Sponsor: UCB, Inc.
Recruiting - verified September 2010
Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Interventions: Drug: RAD001; Drug: sunitinib
Sponsor: Novartis Pharmaceuticals
Recruiting - verified September 2010
Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: cixutumumab; Drug: Hedgehog antagonist GDC-0449; Drug: cisplatin; Drug: etoposide phosphate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: temozolomide; Other: placebo
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

Condition: Advanced Cancer, Various, NOS
Interventions: Drug: BMS-833923; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Bortezomib
Sponsors: Bristol-Myers Squibb; Exelixis
Recruiting - verified June 2010
Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer

Condition: Breast Cancer
Interventions: Drug: systemic chemotherapy; Procedure: axillary lymph node dissection; Procedure: neoadjuvant therapy; Procedure: sentinel lymph node biopsy; Procedure: therapeutic conventional surgery; Procedure: ultrasound imaging
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified September 2010
Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)

Condition: Myocardial Infarction
Interventions: Drug: Prochymal®; Drug: Placebo
Sponsor: Osiris Therapeutics
Recruiting - verified August 2010
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: bortezomib; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: cytarabine; Drug: idarubicin; Drug: mercaptopurine; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: tretinoin; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Treatment De-Intensification and Residual HIV-1 in Youth

Conditions: HIV-1; HIV Infections
Intervention: Other: Blood draw
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH)
Recruiting - verified July 2010
Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ABT-263; Drug: FCR; Drug: BR
Sponsors: Abbott; Genentech
Recruiting - verified June 2010
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma

Condition: Hodgkin's Lymphoma
Intervention: Drug: entinostat (SNDX-275)
Sponsor: Syndax Pharmaceuticals
Recruiting - verified August 2010
Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs

Condition: Epilepsy With Simple or Complex Partial Onset Seizures
Interventions: Drug: Eslicarbazepine acetate; Drug: Eslicarbazepine acetate
Sponsor: Sepracor, Inc.
Recruiting - verified April 2010
Study of Immunotherapy to Treat Advanced Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified July 2010
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Biological: pegfilgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)

Condition: Optic Neuritis
Interventions: Drug: Glatiramer Acetate (Copaxone); Drug: placebo
Sponsor: Teva Pharmaceutical Industries
Recruiting - verified September 2010
A Pharmacokinetics (Blood Levels), Pharmacodynamics (How the Drug Acts on the Body) and Safety Study Dosing of Rabeprazole in New Borns With Gastroesophageal Reflux Disease (GERD).

Condition: Gastroesophageal Reflux
Intervention: Drug: Rabeprazole sodium
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Eisai Inc.
Recruiting - verified August 2010
An Observational Study of Fungal Biomarkers (0000-089)

Condition: Aspergillosis
Intervention: Other: No Intervention
Sponsor: Merck
Recruiting - verified August 2010
Dose Finding Study of HP802-247 in Venous Leg Ulcers

Conditions: Venous Leg Ulcer; Venous Stasis Ulcers
Intervention: Biological: HP802-247
Sponsor: Healthpoint
Recruiting - verified August 2010
Study of EC0489 for the Treatment of Refractory or Metastatic Tumors

Condition: Cancer
Interventions: Drug: EC0489, Injection; Drug: EC20; Drug: EC0489, Injection
Sponsor: Endocyte
Recruiting - verified August 2010
Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)

Condition: Gout
Interventions: Biological: Rilonacept; Other: Placebo
Sponsor: Regeneron Pharmaceuticals
Recruiting - verified August 2010
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery

Condition: Adrenocortical Carcinoma
Intervention: Drug: R-(-)-gossypol acetic acid
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2010
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Conditions: Anemia; Leukemia; Myelodysplastic Syndromes
Interventions: Biological: epoetin alfa; Drug: lenalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
A Trial of Patients With Metastatic Adenocarcinoma of the Pancreas

Condition: Metastatic Pancreatic Cancer
Interventions: Drug: ABI-007/Gemcitabine; Drug: Gemcitabine
Sponsor: Abraxis BioScience Inc.
Recruiting - verified June 2010
Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer

Condition: Carcinoma, Renal Cell
Interventions: Drug: axitinib; Drug: axitinib; Drug: axitinib
Sponsor: Pfizer
Recruiting - verified August 2010
Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: Ipilimumab; Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine
Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified September 2010
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)

Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Cicletanine HC1 or placebo
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Phase III Acute Coronary Syndrome

Condition: Acute Coronary Syndrome
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Pfizer; Duke University
Recruiting - verified April 2010
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Conditions: Adrenocortical Carcinoma; Kidney Cancer; Liver Cancer; Neuroblastoma; Retinoblastoma; Sarcoma
Interventions: Biological: cixutumumab; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
An Open-Label Study of Trastuzumab-MCC-DM1 (T-DM1) vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: capecitabine; Drug: lapatinib; Drug: trastuzumab-MCC-DM1
Sponsors: Genentech; Roche Pharma AG
Recruiting - verified August 2010
Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: aflibercept; Drug: topotecan hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine; Drug: vincristine sulfate; Radiation: fludeoxyglucose F 18
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment

Condition: Metabolic Syndrome
Interventions: Drug: simvastatin; Drug: ezetimibe/simvastatin
Sponsors: University of Maryland; Merck
Recruiting - verified August 2010
Post-Market Study of the 3DKnee™ System

Conditions: Degenerative Joint Disease; Osteoarthritis; Rheumatoid Arthritis; Traumatic Arthritis
Intervention: Device: 3DKnee™ System
Sponsor: Encore Medical, L.P.
Recruiting - verified August 2010
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)

Condition: Pulmonary Hypertension
Interventions: Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Placebo
Sponsor: Bayer
Recruiting - verified August 2010
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.

Condition: Pulmonary Hypertension
Interventions: Drug: Riociguat (BAY63-2521); Drug: Placebo
Sponsor: Bayer
Recruiting - verified August 2010
Paramedic Treatment of Prolonged Seizures by Intramuscular Versus Intravenous Anticonvulsant Medications

Condition: Status Epilepticus
Interventions: Other: Intramuscular route of active treatment; Other: Intravenous route of active treatment
Sponsors: University of Michigan; Medical University of South Carolina; University of California, San Francisco; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified June 2010
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

Conditions: Endometrial Cancer; Fatigue; Neurotoxicity
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: brachytherapy; Radiation: intensity-modulated radiation therapy; Radiation: radiation therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer

Condition: Metastatic Non-small Cell Lung Cancer
Interventions: Drug: CS7017 tablets; Drug: Paclitaxel; Drug: Carboplatin
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified August 2010
I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation

Conditions: Delayed Graft Function; Kidney Transplant
Interventions: Drug: I5NP; Drug: Saline
Sponsor: Quark Pharmaceuticals
Recruiting - verified September 2010
Study of Ataluren (PTC124™) in Cystic Fibrosis

Condition: Cystic Fibrosis
Interventions: Drug: Ataluren (PTC124); Drug: Placebo
Sponsors: PTC Therapeutics; Genzyme; Cystic Fibrosis Foundation
Recruiting - verified September 2010
Post-marketing, Observational Study of HUMIRA® (Adalimumab) in Patients With Chronic Plaque Psoriasis (Ps)

Condition: Chronic Plaque Psoriasis
Intervention: Biological: HUMIRA® (adalimumab)
Sponsor: Abbott
Recruiting - verified August 2010
Capecitabine, Gemcitabine, and Radiation Therapy in Treating Patients With Cholangiocarcinoma of the Gallbladder or Bile Duct

Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Ixabepilone (Ixempra); Drug: Paclitaxel (Taxol)
Sponsors: Sarah Cannon Research Institute; Bristol-Myers Squibb
Recruiting - verified August 2010
PEAK: A Phase 2 Study of Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer Subjects With Wild-Type KRAS Tumors

Conditions: Colon Cancer; Colorectal Cancer; Rectal Cancer; Metastatic Colorectal Cancer
Interventions: Drug: Panitumumab; Drug: Bevacizumab; Drug: mFOLFOX6
Sponsor: Amgen
Recruiting - verified September 2010
Bevacizumab and Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: ixabepilone; Drug: paclitaxel; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2010
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: vedolizumab; Other: Placebo
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified September 2010
Phase II Study of Digitoxin to Treat Cystic Fibrosis

Condition: Cystic Fibrosis
Interventions: Drug: digitoxin; Drug: digitoxin; Other: placebo
Sponsors: Johns Hopkins University; FDA Office of Orphan Products Development
Recruiting - verified August 2010
Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

Conditions: Hepatitis B; Human Immunodeficiency Virus; Hepatitis C, Chronic
Interventions: Drug: maraviroc; Drug: etravirine
Sponsors: Pfizer; ViiV Healthcare
Recruiting - verified September 2010
AngelMed for Early Recognition and Treatment of STEMI

Conditions: Acute Myocardial Infarction (AMI); Coronary Occlusion; Acute Coronary Syndrome
Intervention: Device: AngelMed Guardian System
Sponsors: Angel Medical Systems; Symbios Clinical
Recruiting - verified August 2010
Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy

Conditions: Breast Cancer; Chemotherapeutic Agent Toxicity; Fatigue; Neuropathy; Neurotoxicity
Interventions: Dietary Supplement: acetyl-L-carnitine hydrochloride; Other: placebo
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified September 2010
Neuropsychological and Behavioral Testing in Young Patients With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET)

Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Therapy-related Toxicity
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
(ARTEMIS-IPF)Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF

Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: ambrisentan or sugar pill
Sponsor: Gilead Sciences
Recruiting - verified August 2010
Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Biological: tositumomab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Radiation: iodine I 131 tositumomab
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION

Condition: Optic Neuropathy, Ischemic
Intervention:
Sponsor: Pfizer
Recruiting - verified August 2010
A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin; Biological: Bevacizumab; Biological: Bevacizumab
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
CryoSpray Ablation (TM) GI Patient Registry

Conditions: Barrett's Esophagus With or Without Dysplasia; Squamous Dysplasia of the Esophagus; Esophageal Cancer (Any Stage)
Intervention:
Sponsor: CSA Medical, Inc.
Recruiting - verified August 2010
Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder

Condition: Bipolar Disorder
Interventions: Drug: risperidone; Drug: aripiprazole
Sponsor: University of Maryland
Recruiting - verified August 2010
Malaria Challenge With NF54 Strain

Condition: Plasmodium Falciparum Malaria
Intervention: Other: NF54 P. falciparum isolate
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2010
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate to Severe Renal Insufficiency After the Administration of Magnevist

Conditions: Fibrosis; Kidney Failure; Renal Insufficiency
Intervention: Procedure: Lab sample drawn for serum chemistry at baseline visit
Sponsor: Bayer
Recruiting - verified August 2010
An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Drug: MORAb-003 (farletuzumab); Drug: 0.9% Saline
Sponsor: Morphotek
Recruiting - verified August 2010
A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)

Condition: Advanced Solid Tumors
Interventions: Drug: OSI-906 and/or erlotinib; Drug: OSI-906 and/or erlotinib; Drug: OSI-906 and/or erlotinib
Sponsor: OSI Pharmaceuticals
Recruiting - verified May 2010
Follow-Up Study for Exubera

Condition: Diabetes Mellitus
Interventions: Drug: Exubera; Other: Randomized diabetes therapy
Sponsor: Pfizer
Recruiting - verified August 2010
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Conditions: Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorders; Leukemia; Long-term Effects Secondary to Cancer Therapy in Children; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Precancerous Condition; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Other: survey administration; Procedure: assessment of therapy complications; Procedure: long-term screening; Procedure: study of high risk factors
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"

Condition: Methicillin-Resistant S.Aureus
Interventions: Drug: Cephalexin; Drug: Clindamycin; Drug: Trimethoprim-sulfamethoxazole (TS); Drug: Placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2010
Temsirolimus With or Without Megestrol and Tamoxifen in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: megestrol acetate; Drug: tamoxifen citrate; Drug: temsirolimus
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

Conditions: Irritable Bowel Syndrome With Constipation; Chronic Constipation
Intervention: Drug: Linaclotide
Sponsors: Ironwood Pharmaceuticals, Inc.; Forest Laboratories
Recruiting - verified August 2010
Infant Study of Inhaled Saline in Cystic Fibrosis

Condition: Cystic Fibrosis
Interventions: Drug: 7% Hypertonic Saline (HS); Drug: 0.9% Isotonic Saline (IS)
Sponsors: CF Therapeutics Development Network Coordinating Center; Cystic Fibrosis Foundation; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 2010
Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)

Conditions: Systemic Sclerosis; Pulmonary Arterial Hypertension; Pulmonary Hypertension
Intervention:
Sponsor: Actelion
Recruiting - verified August 2010
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Solar Melanoma That Cannot Be Removed By Surgery

Condition: Melanoma (Skin)
Intervention: Drug: dasatinib
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects

Condition: Acute Coronary Syndrome
Interventions: Drug: Clopidogrel; Drug: Prasugrel; Drug: Commercially-available Aspirin
Sponsors: Eli Lilly and Company; Daiichi Sankyo Co., Ltd.; Duke University
Recruiting - verified August 2010
Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy

Condition: Lung Cancer
Interventions: Drug: sunitinib malate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2010
Investigating Superion™ In Spinal Stenosis [ISISS]

Conditions: Lumbar Spinal Stenosis; Neurogenic Intermittent Claudication
Interventions: Device: Superion™ Interspinous Spacer; Device: X-STOP® IPD® Device
Sponsor: VertiFlex, Incorporated
Recruiting - verified September 2010
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)

Condition: Carcinoma, Hepatocellular
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Placebo
Sponsor: Bayer
Recruiting - verified August 2010
A Patient-Centered Approach to Improve Screening for Side Effects of Second Generation Antipsychotics (SGAs)

Conditions: Schizophrenia; Psychotic Disorders
Interventions: Behavioral: Patient-centered computerized tool; Behavioral: Written educational materials
Sponsor: Department of Veterans Affairs
Recruiting - verified August 2010
Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy

Condition: Prostatic Neoplasms
Interventions: Drug: Prednisone; Drug: sunitinib; Drug: Placebo; Drug: Prednisone
Sponsor: Pfizer
Recruiting - verified August 2010
A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced of Refractory Leukemia or Myelodysplastic Syndrome.

Conditions: Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myelodysplastic Syndromes; Leukemia, Lymphocytic, Chronic, B-Cell
Intervention: Drug: JNJ-26481585.
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
EZN-2285 or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: SC-PEG E. coli L-asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
ChemoFx® PRO - A Post-Market Data Collection Study

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Uterine Neoplasms; Endometrial Cancer; Vaginal Cancer; Vulvar Cancer; Cervical Cancer; Lung Cancer; Carcinoid Tumor of Lung; Sarcoma of Lung; Mesothelioma; Colorectal Cancer
Intervention:
Sponsor: Precision Therapeutics
Recruiting - verified August 2010
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: bortezomib; Drug: cytarabine; Drug: etoposide phosphate; Drug: idarubicin
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy

Condition: Multifocal Motor Neuropathy
Interventions: Drug: Immune Globulin Intravenous, 10%; Drug: Immune Globulin Intravenous, 10% or Placebo (0.25% human albumin solution)
Sponsor: Baxter Healthcare Corporation
Recruiting - verified August 2010
Standard Pain Control or Intrathecal Therapy in Controlling Pain in Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

Conditions: Pain; Pancreatic Cancer
Interventions: Drug: morphine sulfate; Device: Medtronic intrathecal pump
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified September 2010
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer

Condition: Esophageal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome

Condition: Coronary Heart Disease
Interventions: Drug: dalcetrapib; Drug: Placebo; Drug: Evidence-based medical care for Acute Coronary Syndrome
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: midostaurin; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2010
Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Condition: Venous Thrombosis
Interventions: Drug: Enoxaparin; Drug: warfarin; Drug: Placebo for apixaban; Drug: Placebo for enoxaparin; Drug: Placebo for warfarin; Drug: apixaban
Sponsors: Bristol-Myers Squibb; Pfizer
Recruiting - verified April 2010
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: alvocidib; Drug: carboplatin; Drug: cytarabine; Drug: etoposide; Drug: mitoxantrone hydrochloride; Drug: sirolimus; Drug: topotecan hydrochloride
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Condition: Venous Thrombosis
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Pfizer
Recruiting - verified August 2010
Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting - verified September 2010
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Conditions: Advanced Non-Small Cell Lung Cancer; Transitional Cell Carcinoma; Soft Tissue Sarcoma; Gastric/Esophageal Adenocarcinoma; Pancreatic Cancer Including Ampulla of Vater
Interventions: Drug: brivanib; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified July 2010
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab

Condition: Breast Cancer
Interventions: Drug: Docetaxel; Drug: Trastuzumab; Drug: Carboplatin; Drug: Bevacizumab; Drug: 5-Fluorouracil; Drug: Epirubicin; Drug: Cyclophosphamide
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); Cancer International Research Group; Hoffmann-La Roche; Genentech
Recruiting - verified August 2010
Effects of Smoking on Opioid Receptor Binding: A PET Study

Condition: Substance-related Discorder
Interventions: Drug: Nicotine; Drug: Carfentanil
Sponsors: National Institute on Drug Abuse (NIDA); John Hopkins Medical Institute
Recruiting - verified August 2010
Efficacy and Safety Study Comparing Lorazepam and Diazepam for Children in the Emergency Department With Seizures

Condition: Status Epilepticus
Intervention: Drug: lorazepam or diazepam
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified July 2010
Coenzyme Q10 in Huntington's Disease (HD)

Condition: Huntington's Disease
Interventions: Drug: coenzyme Q10; Other: placebo
Sponsors: Massachusetts General Hospital; National Institute of Neurological Disorders and Stroke (NINDS); University of Rochester
Recruiting - verified September 2010
Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Conditions: MDS; Myelodysplastic Syndromes; Thrombocytopenia
Interventions: Drug: Placebo; Biological: Romiplostim
Sponsor: Amgen
Recruiting - verified August 2010
Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

Condition: Hypoactive Sexual Desire Disorder
Interventions: Drug: testosterone gel; Drug: placebo gel
Sponsor: BioSante Pharmaceuticals
Recruiting - verified August 2010
A Phase III Trial of ZD4054 (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: ZD4054; Drug: Best supportive care
Sponsor: AstraZeneca
Recruiting - verified August 2010
Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock

Condition: Sepsis
Interventions: Drug: Drotrecogin alfa (activated); Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

Condition: Hypoactive Sexual Desire Disorder
Interventions: Drug: testosterone gel; Drug: placebo gel
Sponsor: BioSante Pharmaceuticals
Recruiting - verified August 2010
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women

Conditions: HIV Infections; Sexually Transmitted Diseases
Intervention: Biological: Quadrivalent human papillomavirus vaccine
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified June 2009
Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity

Conditions: Spasticity; Cerebral Palsy
Intervention: Drug: baclofen
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified July 2010
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
A Study of the Safety and Effectiveness of Doripenem in the Treatment of Patients With Ventilator-associated Pneumonia

Conditions: Pneumonia; Pneumonia, Bacterial
Interventions: Drug: imipenem/cilastatin; Drug: doripenem
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising PSA After Surgery for Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified September 2010
Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: docetaxel; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: PF-04494700; Drug: PF-04494700; Drug: Placebo
Sponsors: Pfizer; Alzheimer's Disease Cooperative Study (ADCS)
Recruiting - verified August 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group
Recruiting - verified September 2010
Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: lestaurtinib; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis

Conditions: Takayasu's Arteritis; Giant Cell Arteritis
Interventions: Drug: Abatacept; Drug: Placebo
Sponsors: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Office of Rare Diseases (ORD); Rare Diseases Clinical Research Network
Recruiting - verified August 2010
VA NEPHRON-D: Diabetes iN Nephropathy Study

Conditions: Kidney Disease; Nephropathy; Type 2 Diabetes
Interventions: Drug: losartan; Drug: lisinopril; Drug: losartan
Sponsor: Department of Veterans Affairs
Recruiting - verified August 2010
An Investigational Drug, PD 0332991, Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.

Condition: Multiple Myeloma
Interventions: Drug: Bortezomib; Drug: Dexamethasone; Drug: PD 0332991
Sponsor: Pfizer
Recruiting - verified August 2010
Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure

Condition: Breast Cancer
Intervention: Drug: anastrozole
Sponsor: University of Michigan Cancer Center
Recruiting - verified September 2010
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia

Condition: Leukemia
Interventions: Biological: anti-thymocyte globulin; Drug: busulfan; Drug: cyclophosphamide; Drug: cyclosporine; Drug: methotrexate; Drug: methylprednisolone; Drug: tacrolimus; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: allogeneic bone marrow transplantation
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: erlotinib hydrochloride; Drug: paclitaxel albumin-stabilized nanoparticle formulation; Radiation: radiation therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2010
Optimizing Treatment for Treatment-Experienced, HIV-infected People

Condition: HIV Infections
Interventions: Drug: Enfuvirtide; Drug: Raltegravir; Drug: Darunavir; Drug: Tipranavir; Drug: Etravirine; Drug: Maraviroc
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); AIDS Clinical Trials Group
Recruiting - verified April 2009
High-Dose or Standard-Dose Radiation Therapy and Chemotherapy in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Conditions: Lung Cancer; Radiation Toxicity
Interventions: Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel; Radiation: 3-dimensional conformal radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B
Recruiting - verified September 2010
Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis

Condition: Aspergillosis
Interventions: Drug: voriconazole; Drug: anidulafungin; Drug: voriconazole
Sponsor: Pfizer
Recruiting - verified August 2010
Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and Stroke in Patients With Acute Coronary Syndrome (TRA•CER) (Study P04736AM2)

Conditions: Atherosclerosis; Myocardial Ischemia; Myocardial Infarction
Interventions: Drug: SCH 530348; Drug: Placebo
Sponsors: Schering-Plough; Duke University
Recruiting - verified August 2010
Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: docetaxel; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures

Condition: Epilepsy
Interventions: Drug: lacosamide; Drug: lacosamide
Sponsor: UCB, Inc.
Recruiting - verified September 2010
Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: topotecan hydrochloride
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus

Conditions: Hepatitis C Virus; HIV Infections
Intervention: Drug: bavituximab
Sponsor: Peregrine Pharmaceuticals
Recruiting - verified August 2010
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Procedure: therapeutic thoracoscopy; Procedure: videothoracoscopy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group; American College of Surgeons; Southwest Oncology Group
Recruiting - verified September 2010
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

Condition: Cancer
Interventions: Drug: cyclophosphamide; Other: laboratory biomarker analysis; Procedure: biopsy; Procedure: cryosurgery
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

Conditions: Neurotoxicity; Pain; Peripheral Neuropathy; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: duloxetine hydrochloride; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2010
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

Condition: Invasive Breast Cancer
Interventions: Drug: doxorubicin; Drug: cyclophosphamide; Drug: paclitaxel; Drug: trastuzumab; Drug: lapatinib
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); GlaxoSmithKline
Recruiting - verified August 2010
Safety and Effectiveness of Raltegravir (MK-0518) in Treatment-Experienced, HIV-Infected Children and Adolescents

Condition: HIV Infections
Interventions: Drug: Raltegravir (MK-0518); Drug: Raltegravir (MK-0518); Drug: Raltegravir (MK-0518)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2009
Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Genetic: DNA ploidy analysis; Genetic: chromosomal translocation analysis; Genetic: fluorescence in situ hybridization; Genetic: polymorphism analysis; Other: immunologic technique; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib

Condition: Renal Cell Carcinoma
Interventions: Drug: Sorafenib; Drug: Temsirolimus
Sponsor: Wyeth
Recruiting - verified August 2010
A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure

Condition: Heart Decompensation
Interventions: Drug: Nesiritide; Drug: Placebo
Sponsor: Scios, Inc.
Recruiting - verified August 2010
Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors

Conditions: Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: ifosfamide; Drug: paclitaxel
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections

Condition: Cytomegalovirus Infections
Interventions: Drug: Valganciclovir; Drug: Placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2010
Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness

Conditions: Venous Thrombosis; Pulmonary Embolism
Interventions: Drug: Apixaban; Drug: Enoxaparin
Sponsor: Bristol-Myers Squibb
Recruiting - verified May 2010
Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: etoposide; Drug: sunitinib malate
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2010
TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)

Condition: Type 1 Diabetes Mellitus
Intervention: Drug: Otelixizumab
Sponsors: Tolerx Inc.; Juvenile Diabetes Research Foundation
Recruiting - verified June 2009
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.

Condition: Neoplasms
Intervention: Drug: SU011248
Sponsor: Pfizer
Recruiting - verified August 2010
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation

Condition: Pulmonary Embolism
Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939); Drug: Enoxaparin followed by VKA
Sponsors: Bayer; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: AC regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B
Recruiting - verified September 2010
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia

Conditions: Cognitive/Functional Effects; Leukemia; Long-term Effects Secondary to Cancer Therapy in Children; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment
Interventions: Genetic: microarray analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: cognitive assessment; Procedure: diffusion tensor imaging; Procedure: management of therapy complications; Procedure: psychosocial assessment and care
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Comparison of DISCOVER™ Artificial Cervical Disc and ACDF for Treatment of Cervical DDD (IDE Study)

Condition: Cervical Degenerative Disc Disease
Interventions: Device: Arthroplasty (DISCOVER™ Artificial Cervical Disc); Device: ACDF (allograft with SLIM LOC® Anterior Cervical Plate System)
Sponsor: DePuy Spine
Recruiting - verified August 2010
A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection

Condition: Hepatitis B, Chronic
Intervention: Drug: Entecavir
Sponsor: Bristol-Myers Squibb
Recruiting - verified May 2010
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial

Conditions: Cancer; Colon Cancer; Colorectal Cancer; Metastatic Cancer; Rectal Cancer; Metastatic Colorectal Cancer
Interventions: Drug: FOLFIRI - Panitumumab; Drug: FOLFIRI - Bevacizumab
Sponsor: Amgen
Recruiting - verified August 2010
Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: busulfan; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: decitabine; Drug: etoposide; Genetic: cytogenetic analysis; Procedure: autologous bone marrow transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)

Conditions: Vesico-Ureteral Reflux; Urinary Tract Infections
Interventions: Drug: Trimethoprim-Sulfamethoxazole; Drug: Placebo
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified September 2010
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Inflammatory Abnormalities in Muscle After Stroke: Effects of Exercise

Conditions: Stroke; Inflammation
Intervention: Other: Chronic stroke treadmill exercise to improve function
Sponsor: Department of Veterans Affairs
Recruiting - verified August 2010
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission

Conditions: Graft Versus Host Disease; Leukemia
Interventions: Drug: methotrexate; Drug: sirolimus; Drug: tacrolimus
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cancer Receiving Chemotherapy

Condition: Breast Cancer
Intervention: Drug: chemotherapy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified September 2010
C2P - Phase III:MPowerment and Community Promise

Condition: HIV Infections
Interventions: Behavioral: Printed materials; Behavioral: Peer advocates
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH)
Recruiting - verified July 2010
Bevacizumab, Sorafenib, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer

Condition: Kidney Cancer
Interventions: Biological: bevacizumab; Drug: sorafenib tosylate; Drug: temsirolimus
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Drug: asparaginase; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: thioguanine
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer

Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Pain; Prostate Cancer
Interventions: Dietary Supplement: calcium carbonate; Dietary Supplement: calcium citrate; Dietary Supplement: calcium glucarate; Dietary Supplement: vitamin D; Drug: calcium gluconate; Drug: zoledronic acid; Radiation: samarium Sm 153 lexidronam pentasodium; Radiation: strontium chloride Sr 89
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial

Conditions: Congestive Heart Failure; Heart Failure; Anemia; Cardiovascular Disease; Ventricular Dysfunction
Interventions: Drug: Darbepoetin alfa; Drug: Placebo
Sponsor: Amgen
Recruiting - verified September 2010
VEGF Trap in Treating Patients With Metastatic or Unresectable Kidney Cancer

Condition: Kidney Cancer
Intervention: Biological: aflibercept
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.

Condition: HIV-1
Intervention: Drug: TMC125
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified August 2010
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen

Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; The Cleveland Clinic
Recruiting - verified September 2010
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma

Conditions: Childhood Malignant Fibrous Histiocytoma of Bone; Sarcoma
Interventions: Drug: doxorubicin hydrochloride; Drug: ifosfamide; Other: clinical observation; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors

Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Protocol-driven Hemodynamic Support for Patients With Septic Shock

Conditions: Shock, Septic; Severe Sepsis; Sepsis
Intervention: Procedure: Fluid and Vasopressor Protocol
Sponsor: National Institute of General Medical Sciences (NIGMS)
Recruiting - verified August 2010
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine ditartrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified September 2010
Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer

Condition: Anal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: fluorouracil; Radiation: radiation therapy
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Azacitidine With or Without MS-275 in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Drug: azacitidine; Drug: entinostat
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Cooperative Huntington's Observational Research Trial

Condition: Huntington Disease
Intervention:
Sponsors: HP Therapeutics Foundation; Huntington Study Group
Recruiting - verified August 2010
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified July 2010
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: antiandrogen therapy; Drug: docetaxel
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant

Conditions: Kidney Cancer; Leukemia; Lymphoma; Myelodysplastic Syndromes; Neuroblastoma; Pulmonary Complications; Sarcoma
Interventions: Biological: etanercept; Drug: methylprednisolone
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors

Conditions: Neurofibromatosis Type 1; Sarcoma
Interventions: Biological: filgrastim; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Sarcoma Alliance for Research through Collaboration; National Cancer Institute (NCI)
Recruiting - verified August 2010
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Condition: Adrenocortical Carcinoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: mitotane; Procedure: conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer

Conditions: Head and Neck Cancer; Radiation Toxicity
Interventions: Drug: amifostine trihydrate; Drug: cisplatin; Drug: fluorouracil; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
C2P Mobilization Intervention (Pilot)

Condition: HIV Infections
Intervention: Behavioral: Community Mobilization
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH); National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified July 2010
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Southwest Oncology Group
Recruiting - verified September 2010
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease

Condition: Secondary Hyperparathyroidism
Intervention: Drug: Sensipar (Cinacalcet HCl)
Sponsor: Amgen
Recruiting - verified August 2010
Radiation Therapy in Treating Young Patients With Gliomas

Condition: Brain and Central Nervous System Tumors
Intervention: Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: clinical observation
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Growth Hormone Use in Pseudohypoparathyroidism Type 1a

Conditions: Pseudohypoparathyroidism; Pseudopseudohypoparathyroidism; Albright Hereditary Osteodystrophy
Interventions: Drug: Growth hormone treatment; Drug: Growth Hormone
Sponsors: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; FDA Office of Orphan Products Development; Johns Hopkins University
Recruiting - verified September 2010
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

Condition: Sarcoma
Interventions: Biological: PEG-interferon alfa-2b; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified September 2010
Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia

Conditions: Phobic Disorders; Anxiety; Social Phobia
Intervention: Drug: D-Cycloserine
Sponsor: National Institute of Mental Health (NIMH)
Recruiting - verified January 2010
Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: paclitaxel poliglumex; Other: clinical observation
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin's Disease

Condition: Lymphoma
Interventions: Drug: CHOP regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2010
Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer

Condition: Breast Cancer
Intervention: Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Radiation Therapy Oncology Group; Southwest Oncology Group
Recruiting - verified September 2010
Epratuzumab and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: epratuzumab; Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: lomustine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: AC regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer

Conditions: Breast Cancer; Psychosocial Effects of Cancer and Its Treatment
Interventions: Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2010
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group
Recruiting - verified August 2010
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: iodine I 125; Radiation: palladium Pd 103; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors

Conditions: Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Ovarian Cancer
Interventions: Biological: bleomycin sulfate; Drug: cisplatin; Drug: etoposide; Procedure: conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma

Conditions: Leukemia; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Genetic: chromosomal translocation analysis; Genetic: cytogenetic analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2010
Pharmacokinetic Study of Anti-HIV Drugs During Pregnancy

Condition: HIV Infections
Intervention: Procedure: Pharmacokinetic sampling
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2009
Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: therapeutic immune globulin; Other: clinical observation
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Isotretinoin With or Without Monoclonal Antibody, Interleukin-2, and Sargramostim Following Stem Cell Transplantation in Treating Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma

Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: busulfan; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: University Hospitals, Leicester; National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group
Recruiting - verified September 2010
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Condition: Melanoma (Skin)
Interventions: Biological: recombinant interferon alfa; Other: clinical observation
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; Children's Oncology Group
Recruiting - verified September 2010
Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: flow cytometry
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2010

Find Paid Clinical Trials in Baltimore, Maryland - Database

Find Paid Clinical Trials in Baltimore, Maryland

Paid Clinical Trials and Focus Groups by Location

Featured Sponsors